BAYRY
Bayer AG (ADR)

2,760
Loading...
Loading...
News
all
press releases
BAYRY Begins Phase I Study With KQB548 in KRAS-Mutated Cancers
Bayer and Kumquat launch a phase I study of KQB548, aiming to target various KRAS G12D-mutated tumors like pancreatic, colorectal and lung cancer.
Zacks·3d ago
News Placeholder
More News
News Placeholder
Bayer Reports Positive Data on Cell Therapy for Parkinson's Disease
BAYRY's subsidiary BlueRock reports 36-month data showing its Parkinson's therapy bemdaneprocel remains safe and effective in easing motor symptoms.
Zacks·4d ago
News Placeholder
3 Large Drug Stocks to Watch as Industry Recovers After PFE-Trump Deal
Pfizer's landmark pricing deal with Trump sparks a pharma rally as J&J, Bayer and Novartis emerge as strong contenders for inclusion in one's portfolio.
Zacks·4d ago
News Placeholder
Gilead Resolves Patent Litigations for HIV Treatment Biktarvy
Gilead's settlement on Biktarvy patents delays generic entry until 2036, boosting investor confidence.
Zacks·5d ago
News Placeholder
Can CYTK Clinch a Potential FDA Nod for Its Cardiovascular Drug?
Cytokinetics' aficamten shows superiority over metoprolol in late-stage oHCM trial, boosting investor confidence despite FDA delay.
Zacks·10d ago
News Placeholder
Best Value Stock to Buy for September 26th
BAYRY, CARS and MRX made it to the Zacks Rank #1 (Strong Buy) value stocks list on September 26, 2025.
Zacks·16d ago
News Placeholder
Are Medical Stocks Lagging Adagene (ADAG) This Year?
Here is how Adagene Inc. Sponsored ADR (ADAG) and Bayer Aktiengesellschaft (BAYRY) have performed compared to their sector so far this year.
Zacks·17d ago
News Placeholder
REGN Loses 21.1% Year to Date: Buy, Sell or Hold the Sock?
Regeneron shares slump as Eylea struggles, but Dupixent gains and a strengthening oncology pipeline offer growth potential.
Zacks·27d ago
News Placeholder
Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson, Novartis, Pfizer and Bayer
Big Pharma faces tariff risks, patent cliffs, and regulatory pressure, but innovation and strong pipelines keep Eli Lilly, J&J, Novartis, Pfizer, and Bayer in focus.
Zacks·1mo ago
News Placeholder
5 Large Drug Stocks to Watch Despite Industry & Macro Headwinds
In the Large-Cap Pharmaceuticals industry, Lilly, J&J, Novartis, Pfizer and Bayer are worth retaining amid macro pressure and rising innovation.
Zacks·1mo ago

Latest BAYRY News

View

Advertisement|Remove ads.

Advertisement|Remove ads.